The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2021 | Current state of the art for WM
Chemoimmunotherapy represents a tried a tested approach to Waldenström’s macroglobulinemia (WM). Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the current state of the art for WM management, commenting on the increasing number of agents physicians have at their disposal and the subsequent positive impact this has on patient outcomes. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Disclosures
Jorge Castillo receives research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, TG Therapeutics
